table s1. real-time pcr primer sequences. · cd24 prom1 fgfr3 kdr arg2 fgfr2 tnfsf11 itga6...
TRANSCRIPT
Table S1. Real-time PCR primer sequences.
Target Forward primer Reverse primer base pair
References
CD24 AACTAATGCCACCACCAAGG GGACTTCCAGACGCCATTTG 167 NM_013230.3
GATA3 AGGCAGGGAGTGTGTGAACT CTTCGCTTGGGCTTAATGAG 141 NM_001002295.1
PROM1 (CD133)
ACCGACTGAGACCCAACATC GACCGCAGGCTAGTTTTCAC 172 NM_001145847.1
THBS2 ACCTCCTGTCCCTTGACCTT ATGCCCAATTTTCACTCCAC 173 NM_003247.3
LY96 CTGAAGGGAGAGACTGTGAA GGTTGGTGTAGGATGACAAA 149 NM_015364.4
IL1R1 GGGACTTTACACAGGGACCA TCCTTAGTGGCTGGTGACAG 124 NM_000877.3
CXCR4 GGAAAAGATGGGGAGGAGAG AAGAGGCAAAGGAATGGACA 181 NM_001008540.1
IFIT3 GACGGGTAGGACGATAGGAA TGTTAGCCAGGATGGTCTCA 199 NM_001549.5
FGFR3 ACCTGAAGATGGGAGCCTTT TCCGTTGTACCAGCCTTTTC 145 NM_000142.4
IDO1 TATGACGCCTGTGTGAAAGC TCAGTGCCTCCAGTTCCTTT 155 NM_002164.5
KDR AAGTCGGGAGAGGAGAGAGG CACATGGATTGGCAGAGGCT 182 NM_002253
GAPDH ACAGTCAGCCGCATCTTCTT GGCAACAATATCCACTTTACC 151 NM_002046.5
Figure S1. The expression profiles of somatic cells, hESCs (NTU1) and hiPSCs (iCFB). Genes involved in human immune system and demonstrated significant differential expressions between somatic and pluripotent cells are enlisted. PGCs: primary granulosa cells, PDPCs: primary dermal papilla cells, PFCs: primary foreskin fibroblast cells, iCFBD0: undifferentiated iCFB hiPSCs, NTU1D0: undifferentiated NTU1 hESCs, iCFBD15: 15 days differentiated iCFB hiPSCs and NTU1D15: 15 days differentiated NTU1 hESCs.
(A)
N T U 1 v s P D P CF
old
Ch
ang
e
PR
OM
1C
D2
4C
XC
L5
FG
FR
3T
NF
RS
F1
1A
TN
FS
F1
1S
EM
A4
DK
DR
IDO
1C
LU
LC
KB
MP
7P
RS
S1
6C
XC
L6
HM
MR
IL1
7R
BP
SIP
1A
RG
2F
GF
R2
FG
FR
1IL
1R
1IF
IT3
AN
PE
PT
HB
S1
NT
5E
LY
96
IFI2
7C
D4
4IL
13
RA
2L
GA
LS
1C
CR
L1
DP
P4
SE
RP
INE
1IL
6S
TC
OL
EC
12
TG
FB
2IF
IT2
PD
GF
RA
IFI1
6C
1S
- 1 0
-5
0
5
1 0
N T U 1 v s P F C
Fo
ld C
han
ge
CD
24
PR
OM
1F
GF
R3
KD
RA
RG
2F
GF
R2
TN
FS
F1
1IT
GA
6T
NF
RS
F1
1A
LC
KID
O1
EM
BH
MM
RP
RS
S1
6B
MP
7P
SIP
1C
XC
L5
SE
MA
4D
FG
FR
1IL
17
RB
IL1
R1
CC
RL
1L
Y9
6IF
IT3
C1
SIL
6S
TP
DG
FR
AA
NP
EP
CD
44
IL1
3R
A2
C1
RN
T5
EC
OL
EC
12
IFIT
2IF
I16
DP
P4
LG
AL
S1
CA
SP
1T
HB
S1
IL8
- 1 0
-5
0
5
1 0
N T U 1 v s P G C
Fo
ld C
han
ge
CD
24
TN
FS
F1
1P
RO
M1
IDO
1L
CK
BM
P7
TN
FR
SF
11
AIL
17
RB
FG
FR
1F
GF
R3
KIT
PR
SS
16
PS
IP1
AR
G2
FG
FR
2S
EM
A4
DIT
GA
6E
MB
CX
CL
5H
MM
RIL
8V
CA
M1
IL1
R1
LY
96
SE
RP
INE
1IG
JIF
IT3
IFI2
7C
AS
P1
TG
FB
2N
T5
EIL
6S
TP
DG
FR
AL
GA
LS
1C
D4
4C
1S
IFIT
2IF
I16
DP
P4
TH
BS
1
- 1 0
-5
0
5
1 0
(B)
iC F B v s P D P CF
old
Ch
ang
e
PR
OM
1C
XC
L5
CD
24
TN
FS
F1
1K
DR
IDO
1C
LU
BM
P7
FG
FR
3S
EM
A4
DF
GF
R4
HM
MR
CA
LC
BL
CK
CR
1L
IL1
7R
BA
RG
2F
GF
R2
FG
FR
1K
ITIF
IT3
IL1
R1
TH
BS
1C
D4
4A
NP
EP
NT
5E
LY
96
IL1
3R
A2
IFI2
7IL
13
RA
1S
ER
PIN
E1
CC
RL
1T
GF
B2
IL6
ST
C1
SIF
IT2
IFI1
6P
DG
FR
AC
AS
P1
C1
R
- 1 0
-5
0
5
1 0
iC F B v s P F C
Fo
ld C
han
ge
CD
24
PR
OM
1K
DR
FG
FR
3F
GF
R2
AR
G2
TN
FS
F1
1ID
O1
HM
MR
EM
BIT
GA
6C
AL
CB
LC
KC
XC
L5
FG
FR
4B
MP
7C
R1
LF
GF
R1
SE
MA
4D
IL1
7R
BIL
1R
1C
CR
L1
LY
96
IFIT
3C
1S
CD
44
IL1
3R
A2
C1
RIL
6S
TA
NP
EP
IFIT
2P
DG
FR
AIF
I16
NT
5E
IL1
3R
A1
CA
SP
1T
HB
S1
IL8
SE
RP
INE
1T
GF
B2
- 1 0
-5
0
5
1 0
iC F B v s P G C
Fo
ld C
han
ge
CD
24
TN
FS
F1
1ID
O1
PR
OM
1L
CK
BM
P7
CR
1L
IL1
7R
BK
ITF
GF
R1
CA
LC
BC
XC
L1
2A
RG
2F
GF
R4
FG
FR
2F
GF
R3
CX
CL
5S
EM
A4
DE
MB
ITG
A6
IL8
VC
AM
1IL
1R
1L
Y9
6S
ER
PIN
E1
IFIT
3T
GF
B2
IGJ
CA
SP
1IF
I27
NT
5E
CD
44
IL6
ST F3
OL
R1
PD
GF
RA
IL1
3R
A1
C1
SIF
IT2
IFI1
6
- 1 0
-5
0
5
1 0
(C)
N T U 1 v s P D P CF
old
Ch
ang
e
CX
CL
14
PR
OM
1C
XC
R4
GA
TA
3R
NF
12
8K
DR
OL
R1
TN
FS
F1
5B
MP
7C
D2
4F
GF
R3
TE
KC
YT
L1
CL
UIL
11
NF
AT
C2
FG
FR
2A
RG
2L
AM
P3
TH
BD
TH
BS
2A
NP
EP
IL1
3R
A2
CC
RL
1T
HB
S1
CS
TA
MX
1M
R1
CD
10
9C
D1
4IF
IT3
C1
RIT
GA
4L
Y9
6IC
AM
1C
1S
PS
MB
9P
LX
NC
1C
AS
P1
IGJ
- 1 0
-5
0
5
1 0
N T U 1 v s P F C
Fo
ld C
han
ge
CD
24
PR
OM
1C
XC
R4
GA
TA
3K
DR
FG
FR
2A
RG
2F
GF
R3
TH
BD
TN
FS
F1
5R
NF
12
8N
CA
M1
OL
R1
TE
KB
MP
7N
FA
TC
2C
YT
L1
IL1
1L
AM
P3
CX
CL
14
CC
RL
1T
HB
S2
C1
RC
1S
AN
PE
PIL
13
RA
2L
Y9
6M
R1
CX
CL
6P
SM
B9
IFIT
3C
AS
P1
PL
XN
C1
CD
10
9C
XC
L1
ITG
A4
CX
CL
2IL
8IC
AM
1T
HB
S1
- 1 0
-5
0
5
1 0
N T U 1 v s P G C
Fo
ld C
han
ge
CX
CR
4G
AT
A3
CX
CL
14
CO
LE
C1
2M
ME
BM
P7
TN
FS
F1
5P
RO
M1
CD
24
NF
AT
C2
FG
FR
2T
HB
DA
RG
2L
AM
P3
EG
R2
FG
FR
3T
EK
IL1
1K
DR
CL
UIL
8C
XC
L6
TH
BS
2IG
JV
CA
M1
LY
96
CX
CL
1C
AS
P1
CX
CL
2C
CL
26
PS
MB
9IC
AM
1C
1S
IL1
BC
1R
IFIT
3C
ST
AM
R1
ITG
A4
AN
PE
P
- 1 0
-5
0
5
1 0
(D)
Figure S2. The top 20 up- or down-regulated genes were identified in pluripotent stem cells. Undifferentiated stem cells of (A) NTU1 and (B) iCFB, and differentiated stem cells of (C) NTU1 and (D) iCFB were compared with PDPCs, PFCs and PGCs.
iC F B v s P D P CF
old
Ch
ang
e
CX
CL
14
PR
OM
1C
XC
R4
KD
RG
AT
A3
TE
KF
GF
R3
OL
R1
BM
P7
AR
G2
FG
FR
2C
D2
4R
NF
12
8T
HB
DN
CA
M1
CO
LE
C1
2T
HB
S2
TH
BS
1IL
13
RA
2A
NP
EP
CC
RL
1M
X1
MR
1IT
GA
4C
D1
09
CS
TA
IFIT
3P
LX
NC
1P
SM
B9
LY
96
ICA
M1
ITG
B3
C1
RC
1S
IGJ
CA
SP
1
- 1 0
-5
0
5
1 0
iC F B v s P F C
Fo
ld C
han
ge
CD
24
KD
RP
RO
M1
CX
CR
4A
RG
2F
GF
R2
FG
FR
3G
AT
A3
TH
BD
TE
KN
CA
M1
BM
P7
OL
R1
RN
F1
28
CX
CL
14
CC
RL
1T
HB
S2
IL1
3R
A2
C1
RP
LX
NC
1C
1S
LY
96
PS
MB
9M
R1
AN
PE
PC
D1
09
IFIT
3IT
GA
4C
AS
P1
CX
CL
6T
HB
S1
IL8
CX
CL
2IC
AM
1IT
GB
3
- 1 0
-5
0
5
1 0
iC F B v s P G C
Fo
ld C
han
ge
CX
CL
14
CX
CR
4C
OL
EC
12
MM
EG
AT
A3
AR
G2
BM
P7
PR
OM
1F
GF
R2
TH
BD
CD
24
TE
KF
GF
R3
KD
RN
CA
M1
IL8
CX
CL
6IG
JT
HB
S2
LY
96
PS
MB
9C
AS
P1
CX
CL
2IT
GB
3C
CL
26
ICA
M1
VC
AM
1IF
IT3
ITG
A4
CS
TA
C1
SM
R1
C1
RM
X1
IL1
3R
A2
- 1 0
-5
0
5
1 0
Figure S3. The genetic expression profiles of somatic cells, hESCs (NTU1) and hiPSCs (iCFB) were shown in human immune system (Immunome database and our lab selected genes were enlisted). PGCs: primary granulosa cells, PDPCs: primary dermal papilla cells, PFCs: primary foreskin fibroblast cells, iCFBD0: undifferentiated iCFB hiPSCs, NTU1D0: undifferentiated NTU1 hESCs, iCFBD15: 15 days differentiated iCFB hiPSCs and NTU1D15: 15 days differentiated NTU1 hESCs.
(A)
(B)
Figure S4. The surface expression of CD24 was decreased by rapamycin. (A) H9 differentiated stem cells were treated with 50 ng/ml Rapamycin and analyzed by flow cytometry and (B) CD24 mean value was significantly reduced by rapamycin treatment. Mean ± SEM is based on 6 replicate experiments. using different batches of differential stem cells. *P<0.05.
(A)
(B) (C)
0
1
2
3
4
5
C o n tro l R a p a m yc in
IL-1
0 c
on
cne
tra
tion
pg
/ml
*
02468
1 06 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
C o n tro l R a p a m yc in
TG
Fβ
co
ncn
etr
atio
n p
g/m
l
**
CD4+ CD25
+
5.35%
Control Rapamycin
CD4+ CD25
+
6.61%
(D)
Figure S5. The action of rapamycin affects CD3+CD4+CD25+ human regulatory T cells (Treg) activation and function. (A) The percentage of Treg cells and (B) the expression levels of IL-10 (C) TGFβ and (D) neutralized antibodies against to IL-10 and TGFβ in 15-day rapamycin-treated differentiated stem cells co-cultured with PBMCs compared with the control differentiated stem cells. Mean ± SEM is based on 3–5 replicate experiments using H9 differential stem cells. *P<0.05 and **P<0.01.
Table S2A. The up-regulated genes in undifferentiated stem cells compared to somatic cells.
Comparison (Fold Change) Ranking (Top 10)
Compare to PDPC
Compare to PFC
Compare to PGC
Compare to PDPC
Compare to PFC Compare to PGC
GeneID NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB
ARG2 3.284 3.383 5.307 5.406 3.447 3.545
5 6
BMP7 4.166 4.633 3.636 4.103 3.954 4.421
8
6 6
CALCB
4.287
4.565
3.823
CD24 5.773 5.819 9.653 9.699 5.512 5.559 2 3 1 1 1 1
CLU 4.409 4.726 -1.286 -0.922 0.976 1.327 10 7
CR1L
4.017
4.090
4.060
7
CXCL12
-0.495
-3.747
3.681
CXCL5 5.682 6.587 3.278 4.182 1.764 2.668 3 2
CXCL6 3.994
-1.669
-4.305
EMB 1.800 1.972 4.452 4.624 1.897 2.069
10
FGFR1 2.502 2.872 2.584 3.242 3.773 3.834
9 10
FGFR2 3.079 3.345 5.236 5.501 3.141 3.406
6 5
FGFR3 5.057 4.566 6.017 5.526 3.735 3.244 4 9 3 4 10
FGFR4
4.437
4.165
3.502
HMMR 3.989 4.432 4.376 4.819 1.531 1.974
9
IDO1 4.502 5.030 4.453 4.980 4.513 5.040 9 6
8 4 3
IL17RB 3.643 3.823 2.383 2.564 3.790 3.970
8 8
ITGA6 1.663 1.490 4.745 4.571 2.210 2.037
8
KDR 4.699 5.233 5.690 6.224 0.683 1.217 8 5 4 3
KIT 1.849 2.163 1.277 1.590 3.595 3.908
9
LCK 4.323 4.079 4.498 4.287 4.320 4.510
10
5 5
PROM1 8.036 7.889 8.058 7.911 4.978 4.830 1 1 2 2 3 4
PRSS16 4.019
4.179
3.555
PSIP1 3.532
3.522
3.506
SEMA4D 4.763 4.512 3.278 3.027 2.871 2.620 7 10
TNFRSF11A 4.984
4.670
3.826
5
9
7
TNFSF11 4.844 5.328 4.831 5.315 4.996 5.481 6 4 7 7 2 2
Table S2B. The down-regulated genes in undifferentiated stem cells compared to somatic cells.
Comparison (Fold Change) Ranking (Top 10)
Compare to PDPC
Compare to PFC
Compare to PGC
Compare to PDPC
Compare to PFC
Compare to PGC
GeneID NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB
ANPEP -6.842 -6.513 -6.318 -5.989 -3.511 -3.182 3 5 8 10
C1R -3.625 -3.691 -6.097 -6.163 -3.529 -3.595
8
C1S -4.537 -4.640 -6.885 -6.987 -4.995 -5.097
5 5
CASP1 -3.911 -3.715 -5.301 -5.105 -6.092 -5.896
9 9
CCRL1 -5.441 -5.241 -8.535 -8.335 -3.099 -2.899
2 2
CD44 -6.022 -6.533 -6.267 -6.751 -5.134 -5.544 8 4 9 6
COLEC12 -5.030
-6.064
0.410
DPP4 -5.354
-5.856
-4.461
F3
-2.059
-1.289
-5.317
IFI16 -4.667 -4.514 -5.949 -5.802 -4.910 -4.708
IFI27 -6.220 -5.583 -3.113 -2.476 -6.303 -5.666 7 9
8 10
IFIT2 -4.697 -4.573 -6.052 -5.928 -4.947 -4.823
IFIT3 -7.093 -7.117 -7.139 -7.164 -6.419 -6.443 2 1 4 4 7 6
IGJ -2.989 -2.689 -1.722 -1.422 -6.423 -6.123
6 8
IL13RA1
-5.464
-5.572
-5.261
10
IL13RA2 -5.792 -5.929 -6.173 -6.310 -3.076 -3.213 9 8 10 7
IL1R1 -7.361 -6.950 -9.382 -8.972 -7.483 -7.072 1 2 1 1 3 3
IL6ST -5.230 -4.733 -6.483 -6.055 -5.839 -5.417
6 9
IL8 -0.048 -0.318 -3.844 -4.114 -8.158 -8.428
1 1
LGALS1 -5.555
-5.544
-5.577
10
LY96 -6.232 -6.092 -7.510 -7.370 -7.155 -7.015 6 7 3 3 4 4
NT5E -6.497 -6.120 -6.074 -5.791 -6.007 -5.639 5 6
OLR1
-0.166
-0.837
-5.296
PDGFRA -4.694 -4.139 -6.459 -5.904 -5.837 -5.282
7
SERPINE1 -5.235 -5.438 -3.360 -3.563 -6.719 -6.922
5 5
TGFB2 -4.703 -4.845 -2.791 -2.758 -6.010 -6.162
10 7
THBS1 -6.608 -6.850 -4.572 -4.814 -3.580 -3.822 4 3
VCAM1 0.202 0.601 -0.564 -0.166 -7.641 -7.243
2 2
Table S2C. The up-regulated genes in differentiated stem cells compared to somatic cells.
Comparison (Fold Change) Ranking (Top 10)
Compare to PDPC
Compare to PFC
Compare to PGC
Compare to PDPC
Compare to PFC
Compare to PGC
GeneID NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB
ARG2 3.477 4.766 5.500 6.789 3.639 4.929
10 7 5
6
BMP7 4.916 4.773 4.386 4.243 4.704 4.561 9 9
6 7
CD24 4.488 4.080 8.368 8.345 4.228 3.900 10
1 1 9
CLU 4.136
-1.558
0.703
COLEC12 0.228 0.841 -0.806 -0.194 5.668 6.280
4 3
CXCL14 7.873 8.942 1.862 2.930 5.842 6.911 1 1
3 1
CXCR4 6.646 7.106 6.812 7.272 6.007 6.467 3 3 3 4 1 2
CYTL1 4.146
4.086
-1.268
EGR2 2.007
0.960
3.523
FGFR2 3.660 4.282 6.075 6.438 3.819 4.343
6 6 10 9
FGFR3 4.312 4.904 5.273 5.864 2.991 3.582
7 8 7
GATA3 6.473 5.559 6.775 5.861 5.890 4.976 4 5 4 8 2 5
IL11 4.135
3.705
1.853
KDR 5.444 6.948 6.435 7.939 1.428 2.931 6 4 5 2
LAMP3 3.346
3.225
3.551
MME -2.364 -1.211 -2.082 -0.929 4.812 5.964
5 4
NCAM1 1.877 2.011 4.959 5.093 0.495 0.629
NFATC2 3.915
4.267
3.856
OLR1 5.360 4.789 4.689 4.118 0.230 -0.341 7 8
PROM1 7.399 7.466 7.421 7.488 4.340 4.407 2 2 2 3 8 8
RNF128 5.502 4.077 4.993 3.567 -0.140 -1.565 5
TEK 4.269 5.268 4.428 5.427 2.802 3.801
6
10
THBD 2.013 2.583 5.212 5.430 3.714 4.083
9 9
10
TNFSF15 5.142
5.147
4.567
8
10
7
Table S2D. The down-regulated genes in differentiated stem cells compared to somatic cells.
Comparison (Fold Change) Ranking (Top 10)
Compare to PDPC
Compare to PFC Compare to
PGC Compare to
PDPC Compare to PFC
Compare to PGC
GeneID NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB NTU iCFB
ANPEP -6.724 -5.384 -6.200 -4.860 -3.393 -2.052 2 4 5 10
C1R -4.724 -3.400 -7.196 -5.872 -4.628 -3.304
3 4
C1S -4.513 -3.196 -6.861 -5.543 -4.970 -3.653
4 6
CASP1 -3.391 -2.833 -4.806 -4.333 -5.518 -5.007
8 7
CCL26 -2.162 -1.695 -0.768 -0.302 -5.123 -4.657
10 10
CCRL1 -5.733 -5.327 -8.827 -8.422 -3.391 -2.985 4 5 1 1
CD109 -4.851 -4.856 -4.584 -4.588 -1.782 -1.787 9 9
CD14 -4.839
-1.733
-3.021
10
CSTA -5.102 -4.832 -2.510 -2.240 -4.032 -3.762 6 10
CXCL1 -1.147
-4.535
-5.522
7
CXCL2 0.159 0.627 -3.857 -3.389 -5.400 -4.932
9 8
CXCL6 0.549 1.409 -5.114 -4.254 -7.750 -6.890
9
2 2
ICAM1 -4.560 -4.183 -3.662 -3.285 -5.025 -4.648
IFIT3 -4.822 -4.502 -4.869 -4.549 -4.148 -3.828
IGJ -2.436 -2.860 -1.168 -1.593 -5.869 -6.294
4 3
IL13RA2 -5.777 -5.889 -6.158 -6.270 -3.061 -3.173 3 3 6 3
IL1B -1.576
-1.977
-4.853
IL8 0.020 0.251 -3.776 -3.545 -8.090 -7.859
1 1
ITGA4 -4.618 -4.956 -4.067 -4.405 -3.452 -3.790
8
ITGB3
-3.935
-3.051
-4.904
9
LY96 -4.618 -4.200 -5.896 -5.479 -5.542 -5.124
7 7 6 5
MR1 -5.088 -4.965 -5.135 -5.012 -3.581 -3.458 8 7 8 9
MX1 -5.098 -5.209 -2.846 -2.957 -3.162 -3.273 7 6
PLXNC1 -3.599 -4.425 -4.721 -5.547 -0.013 -0.839
5
PSMB9 -4.287 -4.310 -5.058 -5.081 -5.067 -5.090
10 8
6
THBS1 -5.369 -5.999 -3.112 -3.963 -1.349 -2.971 5 2
THBS2 -6.780 -6.081 -7.349 -6.649 -6.370 -5.670 1 1 2 2 3 4
VCAM1 2.180 3.577 1.414 2.811 -5.663 -4.266
5
Table S3. The gene ontology pathway analysis indicated several significant pathways correlated with the 25 candidate immune genes.
GO_ID Term Number Of Genes p-value p-value_ fdr
p-value_ bonferroni
hsa04512 ECM-receptor interaction 16 4.67E-11 9.91E-09 9.91E-09
hsa04510 Focal adhesion 19 4.16E-08 4.41E-06 8.81E-06
hsa05146 Amoebiasis 12 2.23E-06 1.58E-04 4.73E-04
hsa04350 TGF-beta signaling pathway 8 5.70E-04 3.02E-02 1.21E-01
hsa05219 Bladder cancer 5 1.50E-03 6.34E-02 3.17E-01
hsa04060 Cytokine-cytokine receptor interaction 14 2.07E-03 7.31E-02 4.38E-01
hsa05144 Malaria 5 5.95E-03 1.80E-01 1.00E+00
hsa04610 Complement and coagulation cascades 6 1.04E-02 2.74E-01 1.00E+00
hsa04360 Axon guidance 7 1.85E-02 4.12E-01 1.00E+00
hsa05200 Pathways in cancer 13 1.94E-02 4.12E-01 1.00E+00
hsa05130 Pathogenic Escherichia coli infection 4 4.39E-02 8.16E-01 1.00E+00
Table S4A. Log ratio of the genes expression of undifferentiated pluripotent stem cells compared to somatic cells by Ingenuity Pathway Analysis.
Table S4B. Log ratio of the genes expression of differentiated pluripotent stem cells compared to somatic cells by Ingenuity Pathway Analysis.
PDPC: primary dermal papilla cells, PFC: primary foreskin fibroblast cells, PGC: primary granulosa cells. Human ES cells: NTU1 and human iPS cells: iCFB. *No significant.
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
GATA3 NS* NS NS NS NS NS
THBS4 2.33 2.10 2.58 2.72 2.49 2.97
IDO1 5.13 5.06 5.33 5.96 5.88 6.15
CR1L NS 1.91 2.15 3.46 3.77 4.01
TGFβ2 -4.10 -5.62 NS -4.46 -6.16 -3.72
TGFβ1I1 -5.52 -5.09 -4.88 -5.18 -5.02 -4.81
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
GATA3 6.63 6.09 6.71 5.98 5.44 6.07
THBS4 NS NS NS NS NS NS
IDO1 NS NS NS NS NS NS
CR1L NS NS NS NS NS NS
TGFβ2 NS NS NS NS NS NS
TGFβ1I1 NS NS NS NS NS NS
Table S5A. Up-regulated genes of undifferentiated pluripotent stem cells compare to somatic cells in IPA (Log 2 Ratio).
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
GATA3
RNF128 3.32
2.45 3.31
2.44
OLR1
ARG2 3.70 3.46 5.77 3.68 3.44 5.75
BMP7 2.70 2.60 2.93 2.79 2.69 3.02
IGF1R 1.78 2.22
2.58
EGR2
PILRB
1.18
EMB 2.31 2.05 4.55 2.40 2.14 4.64
CALCA 1.79 2.23 1.68 3.50 3.93 3.38
KIT 2.01 3.81
2.53 4.32
GPR83
TGFB2
THBS4 2.33 2.10 2.58 2.72 2.49 2.97
CALCB
3.56 3.85 3.74
CLEC4A
IDO1 5.13 5.06 5.33 5.96 5.88 6.15
HPRT1 2.22
2.16
1.46
CR1L
1.91 2.15 3.46 3.77 4.01
MIF
0.85
Table S5B. Down-regulated genes of undifferentiated pluripotent stem cells compare to somatic cells in IPA (Log 2 Ratio).
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
THBS2 -4.51 -3.92 -5.06 -4.61
-5.16
THBS1 -8.15 -5.48 -6.45 -8.09 -5.42 -6.39
LGALS1 -5.05 -4.96 -4.74 -4.38 -4.30 -4.08
CD14 -4.42
-4.86
CSTA -4.56
-4.43
HMOX1
-3.71
SERPINE1 -5.06 -6.41
-5.39 -6.75
ACTB
-3.19 -4.10 -4.32 -3.64
CD59 -3.89 -4.11 -4.22 -4.25 -4.48 -4.58
LGALS3 -4.01
-4.42
-4.01
IL1B
-4.59
-4.42
IL6
-3.96 -4.99
-4.52 -5.55
SOD3
-4.92
-4.95
CTSS
CCR1
CD274
IRF1
TGFB1I1 -5.25 -5.09 -4.88 -5.18 -5.02 -4.81
TGFB2 -4.10 -5.62
-4.46 -6.16 -3.72
OLR1
-4.79
-4.72
Table S5C. Up-regulated genes of 15 days differentiated pluripotent stem cells compare to somatic cells in IPA (Log 2 Ratio).
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
GATA3 6.63 6.09 6.71 5.98 5.44 6.07
RNF128 5.62
4.75 3.74
2.87
OLR1 4.20
4.27 3.69
3.76
ARG2 3.55 3.31 5.62 4.26 4.01 6.33
BMP7 3.34 3.24 3.57 2.93 2.83 3.16
IGF1R 2.58 3.02 1.67 2.43 2.86 1.51
EGR2
2.01
1.75
PILRB 1.37 1.53
1.31 1.46
EMB 1.48 1.22 3.72
3.26
CALCA
1.29
1.77 2.20 1.65
KIT
2.12
2.78
GPR83 1.34 1.65 1.29
1.46
TGFB2 2.28
2.76
1.57
THBS4
ALOX5AP
1.03
CALCB
2.76 3.05 2.94
CLEC4A
1.33
IDO1
HPRT1
CR1L
Table S5D. Down-regulated genes of 15 days differentiated pluripotent stem cells compare to somatic cells in IPA (Log 2 Ratio). Human ES cells: NTU1 and human iPS cells: iCFB
NTU1 iCFB
Compare to PDPC
Compare to PGC
Compare to PFC
Compare to PDPC
Compare to PGC
Compare to PFC
THBS2 -6.69 -6.10 -7.24 -7.53 -6.94 -8.08
THBS1 -4.95
-5.17
-3.35
LGALS1 -4.57 -4.49 -4.27 -3.35 -3.27 -3.05
CD14 -4.87 -2.81
-4.51
CSTA -4.83 -3.81
-4.45 -3.44
HMOX1 -4.20 -2.48 -4.12 -4.13
-4.06
SERPINE1 -3.02 -3.24
-3.34 -3.46
ACTB -3.42 -3.64 -2.95 -3.73 -3.95 -3.26
CD59 -2.31 -2.54 -2.64 -3.14 -3.37 -3.47
LGALS3 -2.16
-2.57
IL1B
-4.41
-4.38
IL6
-3.10 -4.13 -2.91 -4.17 -5.20
SOD3
-5.03
-4.82
CTSS
-3.02
-3.08
CCR1
-2.99
-3.00
CD274
-2.52
IRF1
-2.48
TGFB1I1
TGFB2
OLR1